John D. Mendlein is a businessperson who founded Fate Therapeutics, Inc. and Homes for Sudan and who has been the head of 5 different companies. Presently, Dr. Mendlein is Chairman at Kintai Therapeutics, Inc., Chairman of Chimeros Therapeutics and President-Corporate & Product Strategy at ModernaTX, Inc. Dr. Mendlein is also on the board of 7 other companies.

In the past Dr. Mendlein was Independent Director at aTyr Pharma, Inc., Attorney at Cooley LLP, President-Corporate & Product Strategy at Moderna, Inc., Chairman & Chief Executive Officer for Adnexus, Chairman & Chief Executive Officer at Affinium Pharmaceuticals Ltd., Scientist at GlaxoSmithKline Pharmaceuticals SA (Belgium) and Director & Chief Knowledge Officer at Aurora Biosciences Corp.

Dr. Mendlein received a doctorate from the University of California, Los Angeles, an undergraduate degree from the University of Miami and a graduate degree from the University of California, Hastings.